Mailin Dpkens1,2, Tiffany R. Blackwell1,
Farhad Vesuna1, Venu Raman1, Balaji Krishnamachary1,
Zaver M. Bhujwalla1, Dieter Leibfritz2, Kristine Glunde1
1JHU ICMIC Program, Russell H. Morgan
Department of Radiology and Radiological Science, The Johns Hopkins
University School of Medicine, Baltimore, MD, United States; 2Department
of Chemistry and Biology, University of Bremen, Bremen, Germany
Altered
choline phospholipid metabolism in breast cancers provides multiple targets
for anticancer therapy. In addition to
increasing total choline levels, malignant transformation of breast cancer
cells results in a switch from high glycerophosphocholine (GPC) and low
phosphocholine (PC) to low GPC and high PC.
The glycerophosphocholine phosphodiesterase (GPC-PDE) genes
responsible for the low GPC levels in breast cancer cells have not been
identified. Here we demonstrate that
glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5), a gene
encoding a GPC-PDE, is at least partially responsible for the low GPC levels
in breast cancer cells, and may be a useful therapeutic target.